12:10:33 EDT Thu 25 Apr 2024
Enter Symbol
or Name
USA
CA



Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on March 31, 2015

2015-03-27 16:45 ET - News Release

FORT WASHINGTON, Pa., March 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, March 31, 2015 at 8:30 a.m. EDT to discuss fourth quarter and full year 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.

To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 8012202 five to 10 minutes before the start of the call.

A live audio webcast of the call will also be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. Please log on through Vitae's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Vitae's website for 90 days following the call.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs. The company is developing a robust and growing portfolio of novel product candidates generated by Contour®, its proprietary structure-based drug discovery platform.

For additional information, please visit the company's website at www.vitaepharma.com.

CONTACT: INVESTORS:
         Vitae Pharmaceuticals, Inc.
         Richard S. Morris, CPA
         Chief Financial Officer
         (215) 461-2000
         rmorris@vitaerx.com
         
         Westwicke Partners
         John Woolford
         (443) 213-0506
         john.woolford@westwicke.com
         
         MEDIA:
         6 Degrees PR
         Tony Plohoros
         (908) 940-0135
         tplohoros@6degreespr.com

Vitae Logo

© 2024 Canjex Publishing Ltd. All rights reserved.